Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?

被引：33

作者：

Schiavi, Michele Carlo ^{[1
]}

Sciuga, Valentina ^{[1
]}

Giannini, Andrea ^{[1
]}

Vena, Flaminia ^{[1
]}

D'oria, Ottavia ^{[1
]}

Prata, Giovanni ^{[1
]}

Di Tucci, Chiara ^{[1
]}

Savone, Delia ^{[1
]}

Aleksa, Natalia ^{[1
]}

Capone, Carmela ^{[1
]}

Di Mascio, Daniele ^{[1
]}

Meggiorini, Maria Letizia ^{[1
]}

Monti, Marco ^{[1
]}

Zullo, Marzio Angelo ^{[2
]}

Muzii, Ludovico ^{[1
]}

Panici, Pierluigi Benedetti ^{[1
]}

机构：

[1] Univ Rome Sapienza, Umberto Hosp 1, Dept Gynecol & Obstetr Sci & Urol Sci, Viale Policlin 155, I-00161 Rome, Italy

[2] Univ Rome, Dept Surg Week Surg, Campus Biomed, Rome, Italy

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2018年 / 34卷 / 08期

关键词：

Vulvovaginal atrophy; overactive bladder syndrome; ospemifene; sexual function; quality of life; POSTMENOPAUSAL WOMEN; GENITOURINARY SYNDROME; URINARY-INCONTINENCE; ESTROGEN; HEALTH; DYSPAREUNIA; VALIDATION; EFFICACY; IMPACT;

D O I：

10.1080/09513590.2018.1441398

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks. Patients completed the OAB-Q SF, FSFI, FSDS, and SF-36 questionnaires. The patient's satisfaction was also calculated. After 12 weeks, the reduction of urinary symptoms was observed. The OAB-Q symptoms, OAB-Q (HRQL) score were (55.34 +/- 13.54 vs. 23.22 +/- 9.76; p<.0001) and (22.45 +/- 9.78 vs. 70.56 +/- 15.49; p<.0001), before and after treatment. SF-36 questionnaire showed a significant improvement (p < .0001). VHI score increased and the women who regularly practice sexual activity increased after treatment. The total FSFI score increased significantly and the FSDS score changed after 12 weeks (p < .0001). The PGI-I after 12 weeks showed a total success rate of 90.5%. Ospemifene is an effective potential therapy for postmenopausal women with VVA affected by OAB or UUI improving sexual function and quality of life.

引用

页码：666 / 669

页数：4

共 28 条

[11] Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy [J].

DeGregorio, Michael W. ;

Zerbe, Robert L. ;

Wurz, Gregory T. .

STEROIDS, 2014, 90 :82-93

[12] Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder [J].

DeRogatis, Leonard ;

Clayton, Anita ;

Lewis-D'Agostino, Diane ;

Wunderlich, Glen ;

Fu, Yali .

JOURNAL OF SEXUAL MEDICINE, 2008, 5 (02) :357-364

[13] Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy [J].

Goldstein, S. R. ;

Bachmann, G. A. ;

Koninckx, P. R. ;

Lin, V. H. ;

Portman, D. J. ;

Ylikorkala, O. .

CLIMACTERIC, 2014, 17 (02) :173-182

[14] Local oestrogen for vaginal atrophy in postmenopausal women [J].

Lethaby, Anne ;

Ayeleke, Reuben Olugbenga ;

Roberts, Helen .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08)

[15] Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy [J].

Minkin, Mary Jane ;

Maamari, Ricardo ;

Reiter, Suzanne .

INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2013, 5 :133-139

[16] Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause [J].

Nappi, R. E. ;

Palacios, S. .

CLIMACTERIC, 2014, 17 (01) :3-9

[17] Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey [J].

Nappi, Rossella E. ;

Particco, Martire ;

Biglia, Nicoletta ;

Cagnacci, Angelo ;

Di Carlo, Costantino ;

Luisi, Stefano ;

Paoletti, Anna Maria .

MATURITAS, 2016, 91 :74-80

[18] Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use [J].

Pinkerton, JoAnn V. ;

Kagan, Risa .

EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) :2703-2714

[19] Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society [J].

Portman, D. J. ;

Gass, M. L. S. .

MATURITAS, 2014, 79 (03) :349-354

[20] Oestrogens and Overactive Bladder [J].

Robinson, Dudley ;

Cardozo, Linda ;

Milsom, Ian ;

Pons, Montserrat Espuna ;

Kirby, Michael ;

Koelbl, Heinz ;

Vierhout, Mark .

NEUROUROLOGY AND URODYNAMICS, 2014, 33 (07) :1086-1091

← 1 2 3 →